SUMMARY
INTRODUCTION
Chronic or excessive (+)-methamphetamine (METH) use has been a serious problem in today's society [1] . Possible medical treatments currently pursued make use of monoclonal antibodies (mAbs) in various forms [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Of particular interest is a recently engineered singlechain variable fragment (scFv) against METH from anti-METH monoclonal antibody mAb6H4 (IgG,  light chain, 11
) [3, 11] . The affinities of scFv:METH and scFv:AMP complexes have been measured to be 10nM and 20.7 M  respectively [11] . The crystal structure of scFv:METH has been determined to a precision of 1.9 Å [3] . However, questions remains: Do the solution structures of scFv deviate from its crystallographic form with or without a drug molecule bound to it? And, if yes, how and how much? What effects do the deviations have on the binding mechanics? Is there a good agreement between the in vitro experiments and the theoretical predictions of the absolute binding energy based on the standard force fields such as CHARMM [14, 15] ? This paper attempts to answer these questions by performing three sets of in silico experiments.
The first set of in silico experiments are long time equilibration runs of scFv:drug complexes and of drug-free scFv, all in solution. They demonstrate how the solution structures of scFv deviate from its crystallographic form [3] with or without a drug molecule bound to it. In particular, the conformation of the binding pocket is examined by computing the root-meansquare-distance (RMSD) of the residues that constitute the binding pocket. The bottom part of the binding pocket is found to remain close to its crystallographic form whether a drug molecule 4 (METH or AMP) is bound in it or not. The orifice part of the binding pocket, however, deviates substantially from the crystallographic form when no drug molecule is bound in the pocket. It is enlarged so much that there is no steric hindrance to a drug molecule when it enters into the binding pocket. This theoretical prediction implies that the relaxation time for the system to reach equilibrium is very short when scFv is injected into a solution of drugs. It also indicates that the Arrhenius barrier is nearly zero along the binding pathway from the dissociated state to the bound state.
The second set of in silico experiments are nonequilibrium dynamics of pulling the drug molecules out of the binding pocket of scFv and the equilibration runs for drugs to fall back into the binding pocket. They demonstrate that extra water molecules (in addition to the two crystallographic waters) exist inside the binding pocket, underneath the drug molecules. This theoretical finding does not contradict but complement the in vitro experimental study because the extra water molecules could and must have been evaporated from the binding pockets during the crystallization process of the in vitro experiments of structural determination. [3] The third set of in silico experiments are nonequilibrium steered molecular dynamics (SMD) [16] simulations to determine the absolute binding free energies of METH and AMP to scFv. The center-of-mass z-coordinate of a drug molecule (METH or AMP) is pulled towards (forward) and away from (reverse) the binding site, sampling forward and reverse pulling paths.
Mechanic work is measured along the pulling paths. The work measurements are averaged through the Brownian dynamics fluctuation dissipation theorem (DB-FDT) [17, 18] 
RESULTS AND DISCUSSION

Solution structures of scFv
In order to see if and how the solution structure of scFv deviates from its crystallographic form, we performed 20 ns equilibrium molecular dynamics (MD) simulations of the drug-free scFv and 5 ns of the scFv:drug complexes each in a box of water. Significant changes in structure all happened in the first 5 ns of the in silico experiments. Examining the hydrophobicity/hydrophilicity of the residues that constitute the binding pocket of an scFv, we understand the mechanics of its structure changes in solution as follows:
The lower half, the floor of the binding pocket (including GLU 114 and HIS 230) are strongly hydrophilic. This part of the pocket strongly attracts waters and the cationic end of a drug molecule. It is stabilized by waters in the pocket or by the cationic amine group of a drug molecule along with several waters beneath it. The upper half, the orifice of the binding pocket consists of hydrophobic aromatic residues that can interact with one another favorable via the van der Waals interactions. But, a residue on the orifice is outside the range of van der Waals interaction with the residue on the opposite side of the orifice. Here, water molecules serve to destabilize the orifice structure of the scFv crystal. Once a drug (METH or AMP) is bound in the pocket, however, the hydrophobic aromatic ring of the drug molecule is within the van der Waal range of the aromatic rings in the orifice of the binding pocket. They interact favorably to stabilize the structure of the pocket in solution.
To complete this subsection, we add that the solution structure of scFv in the scFv:AMP complex closely resemble that of the scFv:METH complex with one exception to be discussed in the next subsection.
Waters at the binding site in-between drug and scFv
In the crystallographic structure of the scFv:METH complex, there are two waters in the binding pocket between the drug's cationic amine group and GLU 114 residue of scFv. These In experiments (2) and (3), we aim to determine the number of waters in the bound state inside the binding pocket between the protein and the ligand. We run and follow the equilibrium 
EXPERIMENTAL PROCEDURES
System setup
We use the crystallographic structure of Celikel et al [3] (PDB code: 3GKZ). We keep all the crystallographic waters and solvate the protein-drug complex with additional 13,526 TIP3
waters. We use CHARMM 27 force field [15] for intra-and inter-molecular interactions. We use periodic boundary conditions and set the system's pressure and temperature at 1 bar and 300 K respectively. We use NAMD 2.6 [19] as the molecular dynamics engine with a time step of 1 or 2 fs with all hydrogen's covalent bonds set rigid. The damping constant 5.0 / ps   . The long range forces are cut off at 12 Å with a switching distance of 10 Å . We run Langevin dynamics at constant temperature and constant pressure. After the system reaches its equilibrium state, the dimensions of the system are 70 86
Solution structures of scFv
In order to determine how the solution structure of scFv deviates from its crystallographic form, we perform equilibrium Langevin dynamics (LD) runs with and without the drug molecule (AMP or METH) bound to scFv. For the case when scFv is without a drug molecule, 21 ns LD has been conducted. However, significant changes are only present in the first 5 ns. For the case when a drug molecule is bound to scFv, 5 ns LD has been conducted. The results are discussed in the previous sections of this paper.
Waters in-between drug and scFv
To determine how many waters are at the binding site of the protein, we remove the drug molecule (AMP or METH) and place it outside the binding pocket of scFv. We run equilibrium LD for 1 ns while holding the drug's center-of-mass fixed. Then we release the drug's center-ofmass and run equilibrium LD without any constraint to the system. We observe that a drug molecule falls into the binding pocket along with a number of waters as discussed in the previous section.
Absolute binding energies of METH and AMP
We perform SMD [16, 20] and use BD-FDT [17, 18] ). We use the infinitely stiff spring to pull the center-of-mass z-degree of freedom [17] while all the other degrees of freedom of the system follow the equilibrium LD. We divide the whole separation along the z-axis between the dissociated state and the bound state into multiple sections of work done to the system when it is pulled from the left end to a point in the section whose zcoordinate is z . Therefore along the partial path from a point in the section whose z-coordinate is z back to the right end of the section, the work is ( ) ( )
We apply the BD-FDT to each section to map the free-energy landscape over the section as follows [17] :
where A G and ( ) G z are the free energies of the system when the drug's center-of-mass zcoordinate are at the right end of a section and at z, respectively. 
In this way, we map out the free-energy landscape over all the sections between the dissociated state and the bound state. The overall free-energy landscapes of AMP and METH in complex with scFv are shown in Fig. 5 and discussed in the previous section.. CWT1 to CWT2------Crystallographic water.
TABLE AND FIGURE LEGENDS
WT3 to WT5------Water inside the binding pocket but not at the crystallographic water postitions. 
